Still keeping my eye on the Sequenom (SQNM) – but the whole idea with this name was to avoid the small cap “biotech” bipolar experience (either a huge win or a huge loss). Unfortunately, this is what this has now turned to, a coin flip. Probably the most bizarre disclosure I’ve ever been associated with, and I’ve seen many off the wall things in my years in the market.

Per CBSMarketwatch

Shares of beleaguered biotech Sequenom Inc. got a much-needed boost last week in the form of a somewhat favorable report issued by Lazard Capital Markets, but is the stock really that seaworthy?
Sequenom jumped nearly 15% on May 27, after Lazard analyst Sean Lavin upgraded the stock, now trading in the $3 range, to hold from sell, saying he believes it had more potential upside than downside.
While cautioning that the …

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Koninklijke Ahold NV (AHONY) Bio-Imaging Technologies Inc (BITI) CBIZ Inc (CBZ) Command Security Corp (MOC) Continucare Corp (CNU) Daimler AG (DAI) DXP Enterprises Inc (DXPE) Flanders Corp (FLDR) Foster's Group Ltd (FBRWY) Human Genome Sciences (HGSI) Huron Consulting Group (HURN) I-Many Inc (IMNY) James Hardie Industries NV (JHX) Javelin Pharmaceuticals Inc (JAV) Jazz Pharmaceuticals Inc (JAZZ) La Jolla Pharmaceutical Co (LJPC) Life Partners Holdings Inc (LPHI) Lincoln Educational Services Corp (LINC) Metabasis Therapeutics Inc (MBRX) Northern Dynasty Minerals Ltd (NAK) Novavax Inc (NVAX) O'Reilly Automotive Inc (ORLY) Obagi Medical Products Inc (OMPI) Radiant Logistics Inc (RLGT) Ralcorp Holdings Inc (RAH) Reed Elsevier plc (RUK) Republic Services Inc (RSG) ...

Typical of the irony in this market, after buying a large swath of Sequenom (SQNM) yesterday at $21, in after hours comes news of "competition" (i.e. a study of 18 patients). Details found here. Researchers led by Stephen Quake of Stanford University in California created a way to look for the extra chromosomes that cause Down's and similar birth detects in the tiny amounts of fetal DNA that circulate in the mother's blood. Quake's team demonstrated the accuracy of the new genetic test in a small study involving 18 women. Quake said the new test could be widely available in two or three years, and could become a routine prenatal test of a baby's health. Quake said the next step is a larger study involving hundreds of women. Stanford University has filed a patent on the test and two companies are negotiating ...